WallStSmart

Honeywell International Inc (HON)vsIntuitive Surgical Inc (ISRG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Honeywell International Inc generates 272% more annual revenue ($37.44B vs $10.06B). ISRG leads profitability with a 28.4% profit margin vs 12.6%. HON appears more attractively valued with a PEG of 2.01. ISRG earns a higher WallStSmart Score of 62/100 (C+).

HON

Buy

50

out of 100

Grade: C-

Growth: 2.7Profit: 7.5Value: 7.3Quality: 5.0

ISRG

Buy

62

out of 100

Grade: C+

Growth: 8.0Profit: 9.0Value: 4.7Quality: 7.8
Piotroski: 4/9Altman Z: 6.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HONSignificantly Overvalued (-416.2%)

Margin of Safety

-416.2%

Fair Value

$47.19

Current Price

$225.79

$178.60 premium

UndervaluedFair: $47.19Overvalued
ISRGSignificantly Overvalued (-78.8%)

Margin of Safety

-78.8%

Fair Value

$262.88

Current Price

$469.98

$207.10 premium

UndervaluedFair: $262.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HON3 strengths · Avg: 8.7/10
Market CapQuality
$143.53B9/10

Large-cap with strong market position

Return on EquityProfitability
26.1%9/10

Every $100 of equity generates 26 in profit

Free Cash FlowQuality
$1.12B8/10

Generating 1.1B in free cash flow

ISRG5 strengths · Avg: 9.2/10
Operating MarginProfitability
30.2%10/10

Strong operational efficiency at 30.2%

Altman Z-ScoreHealth
6.1810/10

Safe zone — low bankruptcy risk

Market CapQuality
$167.61B9/10

Large-cap with strong market position

Profit MarginProfitability
28.4%9/10

Keeps 28 of every $100 in revenue as profit

Revenue GrowthGrowth
18.8%8/10

18.8% revenue growth

Areas to Watch

HON4 concerns · Avg: 3.5/10
PEG RatioValuation
2.014/10

Expensive relative to growth rate

P/E RatioValuation
32.5x4/10

Premium valuation, high expectations priced in

Price/BookValuation
10.3x4/10

Trading at 10.3x book value

Revenue GrowthGrowth
-3.3%2/10

Revenue declined 3.3%

ISRG3 concerns · Avg: 3.3/10
PEG RatioValuation
2.434/10

Expensive relative to growth rate

Price/BookValuation
9.4x4/10

Trading at 9.4x book value

P/E RatioValuation
59.9x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : HON

The strongest argument for HON centers on Market Cap, Return on Equity, Free Cash Flow.

Bull Case : ISRG

The strongest argument for ISRG centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 28.4% and operating margin at 30.2%. Revenue growth of 18.8% demonstrates continued momentum.

Bear Case : HON

The primary concerns for HON are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : ISRG

The primary concerns for ISRG are PEG Ratio, Price/Book, P/E Ratio. A P/E of 59.9x leaves little room for execution misses.

Key Dynamics to Monitor

HON profiles as a declining stock while ISRG is a growth play — different risk/reward profiles.

ISRG carries more volatility with a beta of 1.68 — expect wider price swings.

ISRG is growing revenue faster at 18.8% — sustainability is the question.

HON generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

ISRG scores higher overall (62/100 vs 50/100), backed by strong 28.4% margins and 18.8% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Honeywell International Inc

INDUSTRIALS · CONGLOMERATES · USA

Honeywell International Inc. is an American publicly traded, multinational conglomerate headquartered in Charlotte, North Carolina. It primarily operates in four areas of business: aerospace, building technologies, performance materials and technologies (PMT), and safety and productivity solutions (SPS).

Intuitive Surgical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.

Want to dig deeper into these stocks?